Huons Lab Presents Preclinical Results of "Hidyfuse" at ASCPT Annual Meeting

On March 4 (local time), Huons Lab announced on March 5 that it had presented a preclinical paper evaluating the potential application of its human-derived hyaluronidase platform, "Hidyfuse," to antibodies and antibody-drug conjugates (ADC) at the Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics (ASCPT), held in Colorado, USA.

Huons Lab conducted pharmacokinetic studies by applying Hidyfuse to 11 types of monoclonal antibodies (mAb) and 3 types of ADCs, comparing them with the original substances. The company explained that the results showed an improvement in the bioavailability of drugs when Hidyfuse was applied.

The researchers administered high-concentration formulations of the original substances (antibodies and ADCs) and high-concentration formulations containing Hidyfuse to laboratory mice. According to the company, a comparative pharmacokinetic evaluation showed that the Hidyfuse-based high-concentration formulations increased drug exposure (AUCt) by 116% to 162%, and maximum blood drug concentration (Cmax) by 113% to 170% compared to the original substances. Furthermore, even when the antibody dosage in the Hidyfuse-based formulation was reduced by approximately 25%, the AUCt and Cmax remained equivalent to those of the original high-concentration formulation.

Huons Lab expects that utilizing the Hidyfuse-based formulation technology could reduce the dosage of antibody drugs administered subcutaneously (SC) while maintaining similar drug exposure and efficacy. The company also believes that the Hidyfuse platform could be expanded as a universal platform applicable not only to antibody and ADC drugs, but also to next-generation biopharmaceuticals such as nucleic acid therapeutics, bispecific antibodies, and targeted protein degraders (PROTAC).

A Huons Lab representative stated, "We expect that the Hidyfuse platform-based formulation technology can be used for the development of subcutaneous formulations not only for antibody and ADC-based therapeutics but also for various next-generation biopharmaceutical modalities," adding, "We plan to continue research and development to broaden the application scope of this technology."

This content was produced with the assistance of AI translation services.